Effect of Whole-Body Vibration on Plasma Sclerostin Level
NCT ID: NCT01310335
Last Updated: 2016-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2011-04-30
2011-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Fifteen healthy young adult women are planned to include in this study. All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period. Training duration will be short at the beginning but progressed slowly.
The amplitude of vibration will be 2 mm and the frequency of the vibration will be 40 Hz. The subjects will be asked to report negative side effects or adverse reactions in their training diary.
Previbration and postvibration (just after, 10.minute and 30.minute) levels of plasma sclerostin will be measured on first, second and fifth day of experiment. Sclerostin levels will be measured by human sclerostin ELISA kit.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Bone on Vibration-Induced Muscle Strength Gain
NCT01310348
Whole Body Vibrations on Functional Capacity, Muscular Strength, and Biochemical Profile in Elders
NCT03030456
The Effect of Whole Body Vibration Training on Trunk Muscle Strength, Body Composition and Performance Parameters
NCT05014958
Whole Body Vibration and Tonic Vibration Reflex
NCT05209945
Whole Body Vibration Training on Body Composition
NCT02571322
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Sclerostin, the protein product of the SOST gene, is an osteocyte-specific cysteine knot-secreted glycoprotein that is a potent inhibitor of bone formation. Sost/sclerostin levels have been reported to be reduced by mechanical stimulation.
The aim of this study is to investigate effect of whole-body vibration on plasma sclerostin level in healthy young adult women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Training
The whole-body vibration (WBV) training
whole-body vibration (WBV)
All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
whole-body vibration (WBV)
All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Women with ages varying between 20 and 40 years
* Right-handed women
Exclusion Criteria
1. Orthopedic problems: shortness of legs, congenital anomalies, etc.
2. Joint disease (arthritis, joint prosthesis, etc.)
3. Other painful pathologies in the lower extremities (fractures, tendinitis,bursitis, etc.)
4. Circulation problems in the lower extremities
* Dorsolumbar diseases: Vertebral fract, disc hernias, spondylodiskitis, etc.
* Systemic disease cases
1. Systemic bone disease: osteoporosis, osteomalacia, Paget's disease
2. Hypertension (\>135 mmHg systolic, \>85 mmHg diastolic)
3. Heart dis.(coronary dis, conduction/rhythm prob, cardiac pacemaker)
4. Infectious diseases
5. Endocrine diseases (Diabetes mellitus etc)
* Neurological diseases (CNS problems, peripheral neuropathy)
* Menstrual cycle disorders, amenorrhea, lactation, oral contraceptive use
* Cases during the ovulatory period (11-16th day of menses)
* Obesity (BMI \>30 kg/m2) or low BMI (BMI \<20 kg/m2)
* Vertigo
* Cognitive function disorders
* Women whose blood samples were not taken in the time planned
* Women whose blood samples hemolyzed
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bagcilar Training and Research Hospital
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ilhan Karacan, Clinical Associated Professor
Chief of Physical Med & Rehab Clinic
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ILHAN KARACAN, MD
Role: STUDY_CHAIR
Bagcilar Training & Research Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bagcilar Training & Research Hospital
Istanbul, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
BEAH FTR-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.